Balancing the cellular budget: lessons in metabolism from microbes to cancer

Cancer cells are often seen to prefer glycolytic metabolism over oxidative phosphorylation even in the presence of oxygen-a phenomenon termed the Warburg effect. Despite significant strides in the decades since its discovery, a clear basis is yet to be established for the Warburg effect and why cancer cells show such a preference for aerobic glycolysis. In this review, we draw on what is known about similar metabolic shifts both in normal mammalian physiology and overflow metabolism in microbes to shed new light on whether aerobic glycolysis in cancer represents some form of optimisation of cellular metabolism. From microbes to cancer, we find that metabolic shifts favouring glycolysis are sometimes driven by the need for faster growth, but the growth rate is by no means a universal goal of optimal metabolism. Instead, optimisation goals at the cellular level are often multi-faceted and any given metabolic state must be considered in the context of both its energetic costs and benefits over a range of environmental contexts. For this purpose, we identify the conceptual framework of resource allocation as a potential testbed for the investigation of the cost-benefit balance of cellular metabolic strategies. Such a framework is also readily integrated with dynamical systems modelling, making it a promising avenue for new answers to the age-old question of why cells, from cancers to microbes, choose the metabolic strategies they do.

💡 Research Summary

This review tackles the long‑standing question of why cancer cells preferentially use aerobic glycolysis—the Warburg effect—by comparing it with overflow metabolism observed in microbes. The authors argue that the traditional view of a simple “switch” between oxidative phosphorylation (OXPHOS) and fermentation is insufficient. Instead, they propose that cells allocate limited resources (enzymes, substrates, energy carriers) to satisfy multiple, often competing objectives: rapid ATP production, provision of biosynthetic precursors, mitigation of oxidative stress, and adaptation to fluctuating environmental conditions.

The paper first outlines the historical development of Warburg’s hypothesis, noting that many cancers retain functional mitochondria, which undermines the idea that mitochondrial defects alone drive glycolysis. It then surveys three physiological contexts in which non‑cancerous cells adopt glycolytic metabolism despite ample oxygen: (1) tip endothelial cells during angiogenesis, which need fast membrane extension and migration; (2) activated T‑cells, whose glycolytic burst supports proliferation and cytokine production; and (3) intestinal crypt stem‑cell niches, where glycolytic Paneth cells supply lactate to support neighboring stem cells. These examples illustrate that glycolysis can serve rapid energy supply, NADPH generation, and precursor provision, and can also protect against reactive oxygen species generated by OXPHOS.

Turning to cancer, the authors critique the simplistic “rate‑vs‑yield” trade‑off model. They emphasize that OXPHOS and glycolysis fulfill distinct temporal roles: OXPHOS provides a high‑efficiency baseline flux, while glycolysis offers a fast‑responding, flexible source of ATP and biosynthetic intermediates. Moreover, glutamine metabolism is highlighted as a major carbon source that fuels the TCA cycle and supports nucleotide synthesis, underscoring that OXPHOS also contributes to biosynthesis beyond ATP generation.

The central conceptual framework introduced is “resource allocation,” originally developed to explain microbial metabolic strategies. In this theory, cells distribute limited cellular resources to maximize a composite fitness function that incorporates growth rate, yield, stress resistance, and environmental adaptability. By integrating resource‑allocation models with dynamical systems approaches, the authors propose a quantitative platform that can predict which metabolic configuration (glycolysis‑dominant, OXPHOS‑dominant, or mixed) will be optimal under specific nutrient, oxygen, and signaling conditions. Such models can be calibrated with experimental data (e.g., enzyme expression levels, metabolite concentrations) and used to identify therapeutic vulnerabilities—targeting glycolytic enzymes, glutamine transporters, or regulatory nodes that shift the allocation balance.

In conclusion, the Warburg effect is reframed not as a pathological defect but as an adaptive resource‑allocation strategy that balances speed, efficiency, and biosynthetic needs. By borrowing insights from microbial overflow metabolism, the review provides a unified, systems‑level perspective on cancer metabolism and outlines a roadmap for future quantitative investigations and potential metabolic interventions.